Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Expects to produce 100 million doses of the novel vaccine against dengue fever
Subscribe to our email newsletter
Sanofi-aventis has reported the construction of a new Sanofi Pasteur vaccine manufacturing center in Neuville-sur-Saône, France.
The investment in this new vaccine production facility, which is located close to
Lyon in the Southeast of France, amounts to E350 million and is the largest investment in Sanofi Pasteur’s global vaccines industrial network, said the company.
Reportedly, it would produce 100 million doses of the novel vaccine against dengue fever, currently under development, employ 200 people, and is expected to be operational in 2013.
Christopher Viehbacher, CEO of sanofi-aventis, said: “This new vaccine production center is the largest investment ever made by sanofi-aventis. It illustrates our commitment to providing solutions to unmet medical needs such as dengue, a disease that potentially puts almost half of the world’s population at risk.”